新型逆转录酶抑制剂替诺福韦艾拉酚胺的专利分析  

Patent Analysis of Novel Reverse Transcriptase Inhibitor Tenofovir Alafenamide

作　　者：韩雅婷 王博[1] 张伟波[1] 

机构地区：[1]国家知识产权局专利局化学发明审查部,北京100088

出　　处：《药学进展》2017年第11期857-863,共7页Progress in Pharmaceutical Sciences

摘　　要：为全面系统地反映新型核苷类逆转录酶抑制剂替诺福韦艾拉酚胺的专利情况,对该药物相关的专利技术进行研究,分析其专利申请现状和趋势,重点关注其在中国的专利技术保护情况、原研公司的专利保护策略,为相关研究者针对该类药物的进一步开发和市场运作提供参考。This paper systematically introduced the patent status of novel reverse transcriptase inhibitor tenofovir alafenamide. We investigated its patented technology, analyzed the status and trend of its patent application, and highlighted its patent protection in China and the patent protection strategies of its innovator, so as to provide researchers with references for futrther development and marketing of this drug.

关 键 词：替诺福韦艾拉酚胺 替诺福韦 专利 

分 类 号：R978.7[医药卫生—药品] G306[医药卫生—药学]